Candid Therapeutics merges with Rallybio to advance its autoimmune drug pipeline

At the same time as the backdoor listing, Candid Therapeutics also announced that it has received $505 million in private financing to support its T cell engager product line for the treatment of autoimmune diseases. Lead program cizutamig is expected to begin global Phase 2 testing in myasthenia gravis and interstitial lung disease.

The post Candid Therapeutics merges with Rallybio to advance its autoimmune drug pipeline appeared first on MedCity News.